Overview

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8. This study is configured to explore the safety and efficacy of reparixin in preventing the delayed graft function (DGF) after kidney transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
Dompé Farmaceutici S.p.A